Recursion Announces First Patient Dosed In Phase 1/2 Clinical Study Of REC-1245, A RBM39 Degrader For Biomarker-Enriched Solid Tumors And Lymphoma
Recursion Announces First Patient Dosed In Phase 1/2 Clinical Study Of REC-1245, A RBM39 Degrader For Biomarker-Enriched Solid Tumors And Lymphoma
- First program to result from end-to-end use of OS to identify a novel target and new chemical matter, which moved from target ID to IND enabling studies in under 18 months with ~200 compounds synthesized
- REC-1245 is a potent and selective RBM39 degrader with a potential first-in-class profile in Solid tumors and Lymphoma
- >100,000 patients in the US and EU5 initially addressable
- 這是第一個通過端到端使用操作系統識別新靶點和新化合物的程序，從靶點識別到IND啓用研究不到18個月，合成了約200種化合物。
- REC-1245是一種強效且選擇性的RBM39降解劑，在實體瘤和淋巴瘤中具有潛在的首創類別特徵。
- 美國和歐盟5國初步可針對的患者超過100,000例。
SALT LAKE CITY, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that the first patient has been dosed in its Phase 1/2 clinical trial of REC-1245, a new chemical entity for the treatment of biomarker-enriched solid tumors and lymphoma.
鹽湖城，2024年12月03日（全球新聞通訊社）-- Recursion（納斯達克:RXRX），一家領先的臨床階段科技生物公司，致力於解碼生物學以徹底改善生活，今天宣佈首位患者已在其REC-1245的1/2期臨床試驗中接受劑量治療，該藥物是一種用於治療富含生物標誌物的實體腫瘤和淋巴瘤的新化合物。
Recursion identified the novel regulatory role of RBM39 on CDK12 function using its AI-powered maps of biology. Recursion believes the modulation of RBM39 may be associated with a therapeutic effect in certain biomarker-enriched solid tumors and lymphoma. Preclinical data support that RBM39 degradation induces splicing defects which downregulate DNA Damage Response (DDR) networks and cell cycle checkpoints.
Recursion使用其人工智能驅動的生物學地圖識別了RBM39對CDK12功能的新調節作用。Recursion認爲，調節RBM39可能與某些富含生物標誌物的實體腫瘤和淋巴瘤的治療效果相關。臨床前數據支持RBM39降解導致剪接缺陷，從而下調DNA損傷反應（DDR）網絡和細胞週期檢查點。
譯文內容由第三人軟體翻譯。
